Open AccessAvdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*
Author(s) -
Julien Carvelli,
Ferhat Meziani,
Jean Dellamonica,
Pierre-Yves Cordier,
Jérôme Allardet-Servent,
Megan Fraissé,
Lionel Velly,
Saber Davide Barbar,
Samuel Lehingue,
Christophe Guervilly,
Maxime Desgrouas,
Fabrice Camou,
Christelle Pipéroglou,
Frédéric Vély,
Olivier Demaria,
Joyson Karakunnel,
Joanna Fares,
Luciana Batista,
Federico Rotolo,
Julien Viotti,
Agnès Boyer-Chammard,
Karine Lacombe,
Erwan Le Dault,
Michel Carlès,
N. Schleinitz,
Éric Vivier
Publication year - 2022
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000005683
Subject(s) - medicine , cohort , mechanical ventilation , placebo , randomized controlled trial , cohort study , clinical trial , anesthesia , pathology , alternative medicine